Orchestra BioMed Holdings (OBIO) Return on Capital Employed (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Return on Capital Employed of 58.43% for Q1 2026, up 7356.0% year-over-year from 0.78% in Q1 2025, and down 5.0% quarter-over-quarter from 55.65% in Q4 2025.
Orchestra BioMed Holdings (OBIO) Return on Capital Employed (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Return on Capital Employed for 6 consecutive years, with 58.43% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 7356.0% year-over-year to 58.43%; the TTM figure through Mar 2026 stood at 58.43% (up 7356.0% YoY), while the FY2025 annual figure was 65.76%, up 2678.0% from the prior year.
- Return on Capital Employed declined to 58.43% in Q1 2026 per OBIO's latest filing, from 55.65% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3.35% in Q1 2022 and bottomed at 210.37% in Q2 2025.
- Historically, Return on Capital Employed has averaged 72.55% across 5 years, with a median of 55.65% in 2025.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 11785 bps — and 2026, when it soared 7356 bps.
- Orchestra BioMed Holdings' Return on Capital Employed stood at 51.39% in 2022, then retreated by 6 bps to 54.46% in 2023, then tumbled by 98 bps to 108.0% in 2024, then jumped by 48 bps to 55.65% in 2025, then fell by 5 bps to 58.43% in 2026.
- Business Quant data shows OBIO's Return on Capital Employed at 58.43% in Q1 2026, 55.65% in Q4 2025, and 141.53% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -61.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.23% |
| Mar 31, 2026 | -58.43% |
| Dec 31, 2025 | -55.65% |
| Sep 30, 2025 | -141.53% |
| Jun 30, 2025 | -210.37% |
| Mar 31, 2025 | -131.99% |
| Dec 31, 2024 | -108.00% |
| Sep 30, 2024 | -104.29% |
| Jun 30, 2024 | -92.52% |
| Mar 31, 2024 | -69.28% |
| Dec 31, 2023 | -54.46% |
| Sep 30, 2023 | -49.03% |
| Jun 30, 2023 | -37.24% |
| Mar 31, 2023 | -37.62% |
| Dec 31, 2022 | -51.39% |
| Sep 30, 2022 | -20.16% |
| Jun 30, 2022 | -8.07% |
| Mar 31, 2022 | -3.35% |
| Dec 31, 2021 | -0.24% |